BR112018000592A2 - composição de desbloqueio de nariz congestionado tendo atividade antiviral - Google Patents
composição de desbloqueio de nariz congestionado tendo atividade antiviralInfo
- Publication number
- BR112018000592A2 BR112018000592A2 BR112018000592-4A BR112018000592A BR112018000592A2 BR 112018000592 A2 BR112018000592 A2 BR 112018000592A2 BR 112018000592 A BR112018000592 A BR 112018000592A BR 112018000592 A2 BR112018000592 A2 BR 112018000592A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- adjusting agent
- ionic
- congested nose
- unlock
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229940113118 carrageenan Drugs 0.000 abstract 2
- 235000010418 carrageenan Nutrition 0.000 abstract 2
- 229920001525 carrageenan Polymers 0.000 abstract 2
- 239000000679 carrageenan Substances 0.000 abstract 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002727 hyperosmolar Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
a presente invenção se refere a uma composição farmacêutica que possui uma atividade de desbloqueio de nariz congestionado, caracterizada pelo fato de que a composição compreende uma solução aquosa hiperosmolar de um agente de ajuste de osmolalidade não iônica, opcionalmente em combinação com uma agente de ajuste de osmolalidade iônica, em que a composição compreende ainda o iota carragenano e/ou capa carragenano como um ingrediente ativo antiviral em uma quantidade antiviral eficaz, com a condição de que a composição na sua formulação pronta para uso não contém mais do que 1,5% p/v do agente de ajuste de osmolalidade iônica. a composição é útil para o desbloqueio de um nariz congestionado e para a intervenção profilática ou terapêutica de um número de infecções virais do trato respiratório superior.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176670 | 2015-07-14 | ||
| EP15176670.6 | 2015-07-14 | ||
| PCT/EP2016/066565 WO2017009351A1 (en) | 2015-07-14 | 2016-07-12 | Stuffy nose deblocking composition having antiviral activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018000592A2 true BR112018000592A2 (pt) | 2018-09-11 |
| BR112018000592B1 BR112018000592B1 (pt) | 2024-02-06 |
Family
ID=53717900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018000592-4A BR112018000592B1 (pt) | 2015-07-14 | 2016-07-12 | Composição de desbloqueio de nariz congestionado tendo atividade antiviral |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10660914B2 (pt) |
| EP (1) | EP3370692B1 (pt) |
| JP (1) | JP6774435B2 (pt) |
| KR (1) | KR102628781B1 (pt) |
| CN (1) | CN107847430B (pt) |
| AU (1) | AU2016293004B2 (pt) |
| BR (1) | BR112018000592B1 (pt) |
| CA (1) | CA2992352C (pt) |
| CL (1) | CL2018000033A1 (pt) |
| DK (1) | DK3370692T3 (pt) |
| EA (1) | EA037085B1 (pt) |
| ES (1) | ES2949139T3 (pt) |
| FI (1) | FI3370692T3 (pt) |
| HK (1) | HK1253038A1 (pt) |
| HU (1) | HUE062108T2 (pt) |
| IL (1) | IL256883B (pt) |
| LT (1) | LT3370692T (pt) |
| MA (1) | MA43155A (pt) |
| MX (1) | MX2018000285A (pt) |
| MY (1) | MY194870A (pt) |
| NZ (1) | NZ738597A (pt) |
| PH (1) | PH12018500044A1 (pt) |
| PL (1) | PL3370692T3 (pt) |
| PT (1) | PT3370692T (pt) |
| SA (1) | SA518390689B1 (pt) |
| WO (1) | WO2017009351A1 (pt) |
| ZA (1) | ZA201708595B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013942C (en) * | 2016-02-17 | 2024-03-26 | Ent Technologies Pty Ltd | Compositions and methods for the treatment of sinus disease and disorders |
| GB2567285A (en) * | 2017-08-07 | 2019-04-10 | Suprapharm Cc | Preparation for nasal-nasopharyngeal treatment |
| JP2023517239A (ja) | 2020-03-12 | 2023-04-24 | デイヴィッド カリス－ヒル、シドニー | コロナウイルス感染症および関連するサイトカイン毒性の治療 |
| CN111437270A (zh) * | 2020-04-24 | 2020-07-24 | 瑞希(重庆)生物科技有限公司 | 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法 |
| US11013687B1 (en) * | 2020-06-08 | 2021-05-25 | Amcyte Pharma, Inc. | Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 |
| WO2021253643A1 (zh) * | 2020-06-18 | 2021-12-23 | 大连工业大学 | 硫酸化多糖在抗新型冠状病毒中的应用 |
| CN111686125A (zh) * | 2020-06-18 | 2020-09-22 | 大连工业大学 | 卡拉胶在抗新型冠状病毒中的应用 |
| EP3939597A1 (en) * | 2020-07-16 | 2022-01-19 | Marinomed Biotech AG | Antiviral pharmaceutical composition comprising a carrageenan component |
| FR3113237B1 (fr) | 2020-08-04 | 2023-06-09 | Biopass | Produit pour le traitement de maladies virales par voie nasale |
| US20230330013A1 (en) | 2020-08-04 | 2023-10-19 | Cosmosoft | Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route |
| EP3991561A1 (en) * | 2020-10-28 | 2022-05-04 | Vepidan ApS | Antimicrobial disinfectant gel |
| GB202109888D0 (en) | 2021-07-08 | 2021-08-25 | Pollinner Ltd | Nasal spray |
| KR20230094472A (ko) * | 2021-12-21 | 2023-06-28 | (주)메디코어 | 비강 세정제 조성물 및 그 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2653021A1 (fr) * | 1989-10-17 | 1991-04-19 | Merck Sharp & Dohme | Composition ophtalmique aqueuse liquide a transition de phase liquide-gel. |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| PL2486942T3 (pl) * | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| US20080241271A1 (en) * | 2006-11-08 | 2008-10-02 | Roman Stephen B | Foaming anti-adhesion composition |
| DE602007005697D1 (de) | 2006-12-05 | 2010-05-12 | Marinomed Biotechnologie Gmbh | Verwendung von carrageenan zur behandlung von rhinovirus-infektionen |
| CA2696009C (en) | 2007-08-24 | 2016-08-02 | Marinomed Biotechnologie Gmbh | Antiviral composition comprising a sulfated polysaccharide |
| FR2926218B1 (fr) | 2008-01-10 | 2010-08-13 | Galderma Res & Dev | Composition comprenant un retinoide et du peroxyde de benzoyle disperse. |
| WO2013049538A1 (en) * | 2011-09-30 | 2013-04-04 | Mcneil-Ppc, Inc. | Allergen nasal compositions |
-
2016
- 2016-07-12 LT LTEPPCT/EP2016/066565T patent/LT3370692T/lt unknown
- 2016-07-12 CN CN201680039448.1A patent/CN107847430B/zh active Active
- 2016-07-12 EA EA201890196A patent/EA037085B1/ru unknown
- 2016-07-12 FI FIEP16738419.7T patent/FI3370692T3/fi active
- 2016-07-12 JP JP2017565990A patent/JP6774435B2/ja active Active
- 2016-07-12 KR KR1020187004269A patent/KR102628781B1/ko active IP Right Grant
- 2016-07-12 MX MX2018000285A patent/MX2018000285A/es active IP Right Grant
- 2016-07-12 ES ES16738419T patent/ES2949139T3/es active Active
- 2016-07-12 US US15/767,273 patent/US10660914B2/en active Active
- 2016-07-12 MY MYPI2017704939A patent/MY194870A/en unknown
- 2016-07-12 EP EP16738419.7A patent/EP3370692B1/en active Active
- 2016-07-12 AU AU2016293004A patent/AU2016293004B2/en active Active
- 2016-07-12 PT PT167384197T patent/PT3370692T/pt unknown
- 2016-07-12 DK DK16738419.7T patent/DK3370692T3/da active
- 2016-07-12 HU HUE16738419A patent/HUE062108T2/hu unknown
- 2016-07-12 MA MA043155A patent/MA43155A/fr unknown
- 2016-07-12 BR BR112018000592-4A patent/BR112018000592B1/pt active IP Right Grant
- 2016-07-12 CA CA2992352A patent/CA2992352C/en active Active
- 2016-07-12 PL PL16738419.7T patent/PL3370692T3/pl unknown
- 2016-07-12 WO PCT/EP2016/066565 patent/WO2017009351A1/en active Application Filing
- 2016-07-12 NZ NZ738597A patent/NZ738597A/en unknown
-
2017
- 2017-12-18 ZA ZA2017/08595A patent/ZA201708595B/en unknown
-
2018
- 2018-01-03 SA SA518390689A patent/SA518390689B1/ar unknown
- 2018-01-04 PH PH12018500044A patent/PH12018500044A1/en unknown
- 2018-01-05 CL CL2018000033A patent/CL2018000033A1/es unknown
- 2018-01-11 IL IL256883A patent/IL256883B/en unknown
- 2018-09-27 HK HK18112418.9A patent/HK1253038A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018000592A2 (pt) | composição de desbloqueio de nariz congestionado tendo atividade antiviral | |
| BR102016017090B8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
| MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| BR112018011376A2 (pt) | composição farmacêutica que compreende um inibi-dor de urat1 potente | |
| BR112015028124A2 (pt) | formulação estabilizada de pemetrexed | |
| BR112019003173A2 (pt) | formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica | |
| BR112017016016A2 (pt) | composição de suspensão oftálmica | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112015026053A2 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica | |
| BR112018015851A2 (pt) | composto, e, medicamento. | |
| HRP20191059T1 (hr) | Skup aktivnih sastojaka za topikalnu primjenu u restrukturiranju izmijenjene kožne barijere poslije kožnih bolesti | |
| BR112015027992A2 (pt) | uso de ácido petroselínico para combater desordens estéticas da figura do corpo | |
| HRP20211308T1 (hr) | Veterinarski postupak za izazivanje emeze | |
| BR112017019364A2 (pt) | dispersões sólidas | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
| BR112019003673A2 (pt) | formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica | |
| DOP2016000078A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio | |
| SG11201903834XA (en) | Medical skin external preparation | |
| BR112014015053A2 (pt) | anel vaginal incluindo meloxicam e um agente para modular a liberação do princípio ativo, que pode ser utilizado como um contraceptivo de uso contínuo em mulheres | |
| UA111123C2 (uk) | Застосування комбінованого терапевтичного засобу для лікування риніту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: MARINOMED BIOTECH AG (AT) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2016, OBSERVADAS AS CONDICOES LEGAIS |